top of page
Search

8 Best Pancreatic Cancer Treatment Doctors in India for 2026

Writer: Ganesh Akunoori
Ganesh Akunoori
2 days ago
11 min read

Introduction

You have just received a pancreatic cancer diagnosis. The shock is immediately followed by a crushing realization: the surgery you need costs over $40,000 in the US or UK, and the window for effective intervention is closing fast. Pancreatic cancer moves aggressively. Waiting is not an option, but neither is bankruptcy.

India has reshaped this equation. Here, a Whipple surgery starts at $7,500 and advanced techniques like the NanoKnife at $8,500 offer hope to patients whose tumors were labeled inoperable back home. The cost savings flow from a market correction driven by patient volume and lower operational overhead at hospitals that match global infrastructure benchmarks.

The real differentiator, however, sits beyond the price tag. It is the structural commitment to a formal multidisciplinary tumor board (MTB), a regular meeting of specialists from surgery, medical oncology, radiation oncology, radiology, and pathology who reach a consensus management plan for your case. A 2017 study in HPB (Oxford) established this as the defining feature of a best-practice center. You receive a coordinated institutional verdict rather than a single surgeon's opinion.

This guide maps the nine clinical leaders in India who operate within this tumor-board framework. Each profile grounds itself in the specific technology, institutional volume, and therapeutic philosophy that defines their practice in 2026.

Key Takeaways

Before you commit to a consultation or a flight, three non-negotiable criteria define a top-tier pancreatic cancer specialist in India. These benchmarks separate high-volume multidisciplinary programs from standalone surgical shops.

  • Whipple surgery cost: A pancreaticoduodenectomy in India starts at $7,500, a fraction of the $40,000+ billed in Western hospitals, without sacrificing JCI-accredited safety standards.

  • NanoKnife and Tomotherapy pricing: For locally advanced, borderline-resectable tumors, irreversible electroporation (NanoKnife) is available at approximately $8,500, and Tomotherapy-guided radiation at $5,200. These technologies can convert inoperable cases into manageable disease.

  • Multidisciplinary tumor board (MTB): The single strongest predictor of treatment accuracy is a formal, regularly scheduled MTB. A surgeon, medical oncologist, radiation oncologist, radiologist, and pathologist jointly lock your protocol before any incision happens.

  • Technological infrastructure: Image Guided Radiation Therapy (IGRT) and proton therapy centers exist on-site at top institutions. Demand that your doctor practices at a facility where these are integrated directly into the treatment workflow, not outsourced.

  • Transparent international patient pricing: The best programs operate dedicated international desks that issue invitation letters for medical visas, coordinate FRRO registration, and provide upfront cost estimates without hidden ward-level surcharges. Apollo and Artemis are two names that run this kind of desk.

1. Dr. Bharat Patodiya, Integrative Oncology & Coordinated Care, Pi Cancer Care, Hyderabad

Dr. Bharat Patodiya operates at the intersection of evidence-based medical oncology and integrative supportive care. As the founder of Dr.Bharat Patodiya, he does not practice as a surgeon; he functions as the central coordination layer between you and a vetted network of fellowship-trained surgical oncologists embedded in multidisciplinary cancer centers across India. His practice philosophy acknowledges a blunt truth: a pancreatic cancer diagnosis is a systemic crisis, not just a surgical one, and the preoperative optimization of your nutritional, psychological, and pain status directly influences your ability to tolerate a major resection like the Whipple.

His team builds personalized care plans after evaluating your performance status, biomarker profile, and treatment preferences. The approach is practical and structured. For instance, Dr. Patodiya's program offers chemotherapy packages starting at ₹2.5 to 8 lakhs, inclusive of supportive care components that are often invisible line items in other estimates.

You are not signing up for a single doctor. You are signing up for a 48-hour tumor board review when you upload your imaging and pathology reports, and a single-window system for targeted therapy planning and logistics coordination. This is especially critical for stage 4 pancreatic cancer patients, where FOLFIRINOX can achieve a median overall survival of 11 months. The goal is to get systemic therapy started without the administrative friction that delays dose one.

2. Dr. Vikas Gupta, Surgical Oncology & Multidisciplinary Tumor Board Lead, Artemis Hospitals, Gurgaon

Most JCI-accredited hospitals have a tumor board. Few have a named surgical lead who requires a multi-specialist signoff on every pancreatic case before a scalpel touches skin. At Artemis Hospitals in Gurgaon, Dr. Vikas Gupta holds that role.

Feature

Dr. Vikas Gupta at Artemis, Gurgaon

Standard Community Oncology Practice

Tumor board structure

Led by a designated surgical oncology lead with mandatory radiology, pathology, and medical oncology review for all pancreatic cases

Occasional informal consultations; no mandatory multidisciplinary consensus before surgery

Radiation technology

On-site Image Guided Radiation Therapy (IGRT) integrated directly into treatment planning

External referral for radiation; no real-time imaging guidance during delivery

JCI accreditation

Yes, with corresponding infection control, safety, and quality protocols

Typically not JCI-accredited; variable quality assurance

International patient coordination

Dedicated international desk handling medical visa invitation letters, FRRO registration, and airport pickups

Limited or no structured international patient support; family manages logistics independently

The IGRT capability matters for a specific anatomical reason. In pancreatic cancer, the tumor sits behind the stomach, adjacent to the duodenum and major vessels. A millimeter of radiation drift burns healthy bowel. IGRT captures real-time images immediately before each radiation fraction, correcting your position so the beam hits the tumor, not your duodenum. Without it, you accept a wider margin of collateral damage.

3. Dr. S.V.S. Deo, Head of Surgical Oncology, Apollo Hospital Indraprastha, Delhi

Case volume shapes surgical hands. Apollo Hospital Indraprastha in Delhi runs one of the highest-volume pancreatic surgery programs in North India, and Dr. S.V.S. Deo leads the department that handles this load. For a procedure as technically unforgiving as the Whipple, the center's volume translates directly into lower leak rates and better intraoperative decision-making when anatomy is distorted by tumor invasion.

  • High-volume center: The institutional caseload exposes the surgical team to rare anatomical variants and complex vascular reconstructions that low-volume centers see once a year. This repetition sharpens intraoperative judgement.

  • International patient infrastructure: Apollo operates a dedicated international patient department that issues one-year medical visa invitation letters, assists with FRRO registration, and coordinates airport pickups. That removes the logistical chaos from cross-border care.

  • Transparent cost modeling: Dr. Patodiya's network connects patients to centers like Apollo with upfront cost estimates. The opaque billing practices at some private institutions, where consumables charges inflate the final bill unpredictably, don't apply here.

  • Thorough surgical oncology scope: Dr. Deo's department handles the full spectrum of pancreatic resections, from standard Whipple procedures to distal pancreatectomies with splenectomy, under one roof with integrated critical care backup.

4. Dr. Rajesh Mistry, Thoracic & GI Surgery Specialist, Kokilaben Dhirubhai Ambani Hospital, Mumbai

Pancreatic tumors do not respect anatomical boundaries. A tumor in the body or tail of the pancreas can invade the splenic vessels, the stomach, or the left hemidiaphragm. When the CT scan shows a tumor crossing the diaphragm into the chest, a pure gastrointestinal surgeon hits the limit of their training. Dr. Rajesh Mistry at Kokilaben Hospital in Mumbai operates across that thoracic-abdominal boundary.

This dual specialization is rare. Most surgeons live in one cavity or the other. Dr. Mistry's practice spans both, which means a locally advanced pancreatic body tumor with diaphragmatic invasion or splenic hilum involvement does not require a staged, two-surgeon, two-anesthesia approach. You go under once, and the same set of hands clears the thoracic component and the abdominal disease in a single field.

Kokilaben Dhirubhai Ambani Hospital provides the infrastructure for this work: operating suites built for complex resections, a dedicated surgical intensive care unit, and 24-hour interventional radiology. Those resources matter when post-operative bleeding or an abscess complicates a high-risk pancreatic case. If your tumor is borderline resectable because of local structural invasion, Dr. Mistry's crossover skill set turns that anatomical complexity into a technical problem with a surgical answer.

5. Dr. Adwaita Gore, Medical Oncology, Targeted Therapy & Clinical Trials, Tata Memorial Hospital, Mumbai

A significant subset of pancreatic cancer patients needs a medical oncologist who can match their tumor's genetic alterations to a targeted therapy pill or a clinical trial open at India's largest public cancer research institution. Dr. Adwaita Gore practices medical oncology at Tata Memorial Hospital in Mumbai, a government-run center that houses India's largest oncology tissue bank and runs trials that are inaccessible in private hospitals.

Tata Memorial operates at a cost structure that removes the financial barrier between you and cutting-edge drugs. The institution's research infrastructure means a patient with a KRAS wild-type tumor, an MSI-H status, or a rare BRAF alteration can be matched to an open trial rather than defaulting to the only chemotherapy regimen they can personally afford.

Biomarker testing on biopsy tissue tells the oncologist whether you are a candidate for immunotherapy or a specific pill. The exocrine type is more common and is usually found at an advanced stage, but pancreatic neuroendocrine tumors are less common and have a better prognosis. Dr. Gore handles this diagnostic fork as a core competency.

You should understand the trial option candidly: a clinical trial at Tata Memorial is a public hospital experience with registrations, queues, and wait times. The trade is time and comfort for access to agents like peptide nanovaccines paired with anti-PD-1 antibodies, regimens listed on ClinicalTrials.gov that are years away from commercial availability in the private sector. For a disease where standard chemotherapy hits a survival ceiling, that access can be what lets you keep going when you would otherwise run out of options.

6. Dr. S.H. Advani, Senior Medical Oncologist, Immunotherapy & Palliative Integration, Jaslok Hospital, Mumbai

Dr. S.H. Advani's decades of oncology practice at Jaslok Hospital have placed him at the center of a critical shift in pancreatic cancer care: palliative integration now runs parallel to disease-modifying therapy from day one. His service structures supportive palliative care around symptom control, quality of life optimization, and total patient well-being.

  1. Performance status evaluation: The team evaluates your ECOG status and comorbidity burden to determine whether intensive combination chemotherapy or a less toxic palliative-intent regimen is appropriate; patients with poor performance status may be better suited to less intensive treatment.

  2. Immunotherapy eligibility screening: If your tumor demonstrates MSI-H or dMMR biomarkers, the team accesses checkpoint inhibitors targeting PD-1 and CTLA-4 pathways; if the tumor is MSS, immunotherapy is ineffective and not an option.

  3. Early symptom control: Pain management, nutritional support, and pancreatic enzyme replacement therapy are initiated at the first consultation. Waiting until the patient deteriorates undermines chemotherapy tolerance because malabsorption and nutritional deficiencies go unaddressed.

  4. Home care coordination: For patients unable or unwilling to endure prolonged hospitalization, the model includes home care coordination and the recommendation of best supportive care focused on comfort when curative-intent treatment is no longer viable.

7. Dr. Deepak Chhabra, GI & HPB Surgical Oncology, Nanoknife & Tomotherapy, Medanta, The Medicity, Gurgaon

A pancreatic tumor wrapped around the superior mesenteric artery is a surgical death sentence by the classical textbooks. Dr. Deepak Chhabra at Medanta in Gurgaon deploys two technologies that challenge this fatalism. The first is NanoKnife, a technique of irreversible electroporation (IRE) that uses high-voltage electrical pulses to punch permanent holes in tumor cell membranes without the thermal burn that would destroy the adjacent artery. Priced at approximately $8,500, it is a procedure designed specifically for locally advanced, unresectable pancreatic cancer where the tumor has not yet spread to the liver or peritoneum but has ensnared critical vessels.

The second technology is Tomotherapy, a radiation delivery system that integrates a CT scanner with a linear accelerator, rotating around your body to sculpt the radiation dose precisely to the tumor shape. At $5,200, it achieves dose distributions that spare the duodenum and stomach, organs that conventional radiation always scatters dose across during standard pancreatic bed irradiation.

Dr. Chhabra's GI and HPB surgical oncology specialization means he evaluates you by a sequential logic: can we resect? If not, can we ablate with NanoKnife? If not, can we control locally with Tomotherapy plus systemic chemotherapy? This tiered decision tree, executed at a high-volume HPB unit, converts a substantial percentage of

8. Dr. Hariharan K. Medical Oncology, Home-Based Chemotherapy Programs, Apollo Proton Cancer Centre, Chennai

If you are too weak to travel repeatedly for infusions, a home-based chemotherapy program keeps treatment on track without the physical toll of daily hospital commutes. Dr. Hariharan K. practices at Apollo Proton Cancer Centre in Chennai, South Asia's only proton therapy destination, giving patients access to the most precise form of radiation available when the tumor requires it.

Not every chemotherapy regimen can be administered at home. Safety depends on the drug's infusion time, the risk of acute reactions, and your overall performance status. The center screens candidates carefully.

For regimens that qualify, shifting infusions to the home setting reduces exposure to hospital-acquired infections. This matters when your immune system is already suppressed from disease and treatment. Apollo's program integrates medical oncology oversight with home-care logistics.

You remain under the same oncologist's supervision while the infusion team travels to you. If your treatment plan includes FOLFIRINOX, the center's medical oncology team knows it can achieve a median overall survival of approximately 11 months in appropriately selected metastatic patients. Dr. Hariharan works within a structure that includes a multidisciplinary tumor board: a panel of oncologists, radiologists, and pathologists who review your case to reach a consensus plan.

Conclusion

You need a pancreatic cancer team. The strongest centers in India operate as a single-window system where a multidisciplinary tumor board (a standing committee of surgical, medical, and radiation oncologists plus radiologists and pathologists) reviews your imaging, pathology, and biomarker data before anyone recommends a course of action. This is the standard you should demand.

The exocrine type of pancreatic cancer is more common and is usually found at an advanced stage, which means most patients walk into their first consultation facing stage 4 disease. At that point, the treatment goal is not curative. FOLFIRINOX remains the benchmark systemic option, delivering approximately 11 months median survival in fit patients. For tumors with specific genetic alterations, targeted therapy may apply, but not every stage 4 pancreatic cancer patient qualifies.

Cost planning matters from day one. Whipple surgery starts around $7,500 in India, and chemotherapy packages can vary widely based on regimen intensity, supportive care layers, and whether infusions happen in a hospital daycare unit or at home through a supervised program. Ask every center for an upfront cost estimate that includes drugs, imaging, and supportive medications. Your treatment window is narrow. The right center gives you an answer within 48 hours of uploading your reports and does not make you wait weeks for a tumor board to convene.

Frequently Asked Questions

How much does pancreatic cancer treatment cost in India, and is financial assistance available?

Pancreatic cancer surgery in India starts at $7,500, with Whipple procedures from $10,300, a fraction of the $40,000+ cost in the US. Many major hospitals have dedicated international patient departments that provide detailed cost estimates. While broad financial assistance programs vary widely, you should directly inquire with the hospital’s social work or patient services department about available support and payment plans.

What makes a pancreatic cancer treatment center 'best'?

A top center is defined by three critical indicators:

  1. Multidisciplinary tumor board: surgeons, medical and radiation oncologists, radiologists, and pathologists collaborate on every case, as supported by a 2017 study in HPB (Oxford).

  2. High case volume and cutting-edge technology: expertise in Whipple surgery plus access to tools like Tomotherapy and NanoKnife.

  3. Clinical trial access: availability of next-generation therapies and investigations.

How can international patients access specialized pancreatic cancer care and second opinions in India?

International patients typically access care through hospital-based coordinators at JCI-accredited centers like Artemis Hospitals or Apollo Hospital Indraprastha. These departments handle visa assistance, interpreters, and travel logistics. A remote second opinion is usually the first step, requiring you to securely submit medical records and scans for a formal review by a specialist.

What are the latest targeted therapy and immunotherapy options in India for pancreatic cancer?

Active clinical trials in India are exploring combinations like peptide nanovaccines with anti-PD-1 antibodies and chemotherapy for advanced pancreatic cancer. A leading institution like Tata Memorial Hospital, where an oncologist such as Dr. Adwaita Gore practices, is a central hub for these next-generation immunotherapy and targeted therapy investigations.

What is the role of a multidisciplinary tumor board in pancreatic cancer treatment?

A multidisciplinary tumor board reviews your imaging, pathology, and history to forge a single, coordinated treatment plan. Evidence from an HPB journal study shows this collaborative model often changes the diagnosis or management strategy. This integrated approach inherently supports timely symptom management and decision-making from diagnosis onward, working in tandem with dedicated palliative care.

Sources

Comments

bottom of page